Analyst picks & changes

Biogen Inc.

Chiron Corp.

Analysts reshuffled Biogen Inc. and Chiron Corp. in their portfolios following BGEN's announcement last week that it would file for marketing approval of its beta interferon for multiple sclerosis on the basis of its recently completed Phase III study.


, sold by Berlex and

Read the full 462 word article

How to gain access

Continue reading with a
two-week free trial.